MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, California. Rajeev Saggar, MD, chief medical ...